Keyphrases
Epidermal Growth Factor Receptor
100%
Non-small Cell Lung Cancer (NSCLC)
100%
HER2 Inhibitors
100%
Acquired Resistance
50%
Survival Rate
50%
Clinical Efficacy
50%
Human Epidermal Growth Factor Receptor 2 (HER2)
50%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
50%
Novel Agents
50%
Small Patients
50%
Poor Survival
50%
Clinical Development
50%
Erlotinib
50%
Epidermal Growth Factor Receptor Inhibitors
50%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
50%
Resistance Development
50%
Recurrent Non-small Cell Lung Cancer
50%
Global Health Issue
50%
Irreversible Inhibitor
50%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
66%
Survival Rate
33%
Erlotinib
33%
Diseases
33%